Liver Cancer, Adult
26
12
13
2
Key Insights
Highlights
Success Rate
40% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 60/100
11.5%
3 terminated out of 26 trials
40.0%
-46.5% vs benchmark
0%
0 trials in Phase 3/4
100%
2 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (26)
Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose (RADIANT)
Liver Function Investigation With SPECT
Development of 3D Multi-Parametric Ultrasound (MPUS) as a Decision Support Tool for Patients
RAdiation SEgmentectomy With REsin Microspheres (RASEREM) Study
FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma
A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors
An Innovative CFD-based Dosimetry and Pre-treatment Planning Platform to Support Personalized Transarterial Therapies for Liver Cancer
NIR-II Fluorescence-Guided Hepatectomy Using ICG-Cisplatin Nanoprobes for HCC
T-Cell Therapy (ECT204) in Adults With Advanced HCC
15 vs 45 Minute Pringle Maneuver in Liver Cancer Resection: Randomized Noninferiority Trial
International Study on Treatment of Patients With Metastatic Colorectal Liver Lesions Patients With IRE
International Study on Treatment of Liver (HCC) Patients With IRE
To Test Whether Time-restricted Eating Coupled With a Healthy Diet is Beneficial in Liver Cancer Patients
Novel Method to Assess Hepatic Regeneration and Predict Hepatic Related Morbidity After Partial Hepatectomy
Digital Early Warning System for Acute Lung Injury in Liver Surgery
The Diagnostic Efficacy and Lesion Detection Advantages of 18F-FDG PET/Contrast-enhanced MRI in Malignant Liver Lesions
AI-Driven Quantitative Decision and Surgical Planning System for Liver Cancer
Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC
Immunophenotype of PBMC to Early Predict Response to Immunotherapy in Hepatocellular Carcinoma